KLOW stack[KPV + BPC-157 + TB-500 + GHK-Cu blend]
Compound snapshot
Class
Informal community blend
FDA approved
Research use only — an informal community blend, not an approved medicine
Clinical development
Discovery
Last reviewed
September 2026
Research areas
Community blend / Recovery / Tissue repair
Regulatory status
Research use only — an informal community blend, not an approved medicine
Internet attention
High
Registry query
KLOW stack
The four-peptide extension of GLOW, adding KPV for anti-inflammatory coverage. Vendors commonly sell it at ratios such as 50 mg BPC-157 / 10 mg TB-500 / 10 mg GHK-Cu / 10 mg KPV in one vial, though ratios differ widely between sellers.
Reality check — what we actually know
Supported by human evidence
- This compound has completed human trials in at least one approved indication — see the regulatory section for what was actually approved.
Animal research only
- The broadest of the three blends on paper, covering four described pathways
- Discussed for chronic joint and soft-tissue irritation as well as skin
- One reconstitution rather than four separate vials
Mechanistically plausible
- Three compounds are framed around structural repair — blood-vessel growth, cell migration and matrix remodelling — while KPV is framed around the inflammatory environment in which repair happens, through NF-kB-linked cytokine signalling.
Common internet claims
- Online discussion frequently presents KLOW stack as a proven treatment rather than a research compound.
Not established
- Human efficacy for the outcomes commonly claimed
- Optimal route, quantity and duration in humans
- Long-term human safety
Evidence distribution
Each band is a live PubMed search for KLOW stack, filtered to that kind of study. Top is the strongest evidence; the base is reasoning, not proof. A band with no records means that kind of study has not been published for this compound yet.
Mechanism and reported findings
Three compounds are framed around structural repair — blood-vessel growth, cell migration and matrix remodelling — while KPV is framed around the inflammatory environment in which repair happens, through NF-kB-linked cytokine signalling.
- The broadest of the three blends on paper, covering four described pathways
- Discussed for chronic joint and soft-tissue irritation as well as skin
- One reconstitution rather than four separate vials
Strength of the evidence: The thinnest evidence of the family. No study has tested KLOW in any species, KPV itself has no human trials, and its anti-inflammatory rationale overlaps with activity already claimed for the other three. Each added compound makes any side effect harder to attribute.
Safety and known cautions
Four unapproved compounds in one vial: no human safety data for the combination, no established dose, and no way to know which component caused a reaction. Purity, ratios and labelling depend entirely on the vendor. Not a treatment for injury, arthritis, gut disease or autoimmune conditions — those need a clinician.
Evidence at a glance
No single score, on purpose. The line beside each bar shows how much reported outcomes vary between studies.
Development stage
- DiscoveryCurrent
- Preclinical
- Phase 1
- Phase 2
- Phase 3
- Regulatory review
- Approved